Combination regimens using progesterone receptor modulators

US6444668B1 · kind B1 · utility

Assignees

• Wyeth, LLC · US
• Ligand Pharmaceuticals Incorporated · US

Inventors

• Gary S. Grubb · Newtown Square, US
• Puwen Zhang · Audubon, US
• Eugene A. Terefenko · Quakertown, US
• Andrew Fensome · Wayne, US
• Jay E. Wrobel · Lawrenceville, US
• Horace Fletcher, III · Pottstown, US
• James P. Edwards · San Diego, US
• Todd K. Jones · Solana Beach, US
• Christopher M. Tegley · Thousand Oaks, US
• Lin Zhi · San Diego, US

Key dates

• Filing date: Apr 19, 2000
• Grant date: Sep 3, 2002
• Expiry date: Apr 19, 2020

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K31/56
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

This invention relates to cyclic combination therapies and regimens utilizing substituted indoline derivative compounds which are antagonists of the progesterone receptor having the general structure: wherein R1 and R2 may be single substituents or fused to form spirocyclic or hetero-spirocyclic rings; R3 is H, OH, NH2, C1 to C6 alkyl, substituted C1 to C6 allyl C3 to C6 alkenyl, substituted C1 to C6 alkenyl, alkynyl, or substituted alknyl, CORC; RC is H, C1 to C3 alkyl, substituted C1 to C3 alkyl, aryl, substituted aryl, C1 to C3 alkoxy, substituted C1 to C3 alkoxy, C1 to C3 aminoalkyl, or substituted C1 to C3 aminoalkyl; R4 is H, halogen, CN, NO2, C1 to C6 alkyl, substituted C1 to C6 alkyl alkynyl, or substituted alkynyl, C1 to C6 alkoxy, substituted C1 to C6 alkoxy, amino, C1 to C6 aminoalkyl, or substituted C1 to C6 aminoalkyl; and R5 is selected from a trisubstituted benzene ring of a five or six membered ring with 1, 2, or 3 heteroatoms from the group including O, S, SO, SO2 or NR6 and containing one or two independent substituents from the group including H, halogen, CN, NO2, amino, and C1 to C3 alkyl, C1 to C3 alkoxy, C1 to C3 aminoalkyl, CORF, or NRGCORF; or pharmaceutical…